GlassScriptPhysician profile
Bryant F Williams
NPI 1053396606
$2,155.64
in general payments reported to CMS, 2019-2025
21 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $363 · 2021: $218 · 2022: $66.29 · 2023: $297 · 2024: $445 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $503.44 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $292.84 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $269.26 | 2019-2025 | |
| Coloplast Corp | $194.00 | 2019-2024 | Titan |
| Janssen Biotech, INC. | $143.93 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $124.19 | 2019-2025 | Axonics, Lumenis Pulse 120h |
| Medtronic, INC. | $96.24 | 2025 | Interstim |
| Axonics, INC. | $83.29 | 2022-2024 | Axonics |
| Laborie Medical Technologies Corp. | $79.59 | 2024 | Urgent PC Neuromodulation System, Endosheath Technology |
| Abbvie INC. | $78.20 | 2023-2024 | Botox |
| Antares Pharma, INC. | $54.67 | 2024-2025 | Xyosted |
| Procept Biorobotics Corporation | $49.69 | 2024 | Aquabeam System |
| Endo Pharmaceuticals INC. | $46.29 | 2019-2023 | Xiaflex, Aveed |
| Amgen INC. | $28.63 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $24.14 | 2025 | Prolaris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $19.53 | 2024 | Illuccix |
| C. R. Bard, INC. & Subsidiaries | $16.61 | 2019 | |
| Rochester Medical Corporation | $15.73 | 2019 | |
| Myovant Sciences INC. | $15.49 | 2021 | |
| Allergan, INC. | $12.29 | 2021 | |
| Travere Therapeutics, INC. | $7.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.